Fermenta Biotech Approves Rs 1.50 Billion Fundraising For Capacity Expansion

Fermenta Biotech Ltd, a leading pharmaceutical and biotechnology company, announced that its board has approved a proposal to raise funds not exceeding Rs 1.50 billion. The capital will be deployed towards capacity expansion and investments in high-growth business verticals, including Vitamin D3, Vitamin D3 derivatives, and green chemistry enzymes. This strategic move highlights the company’s commitment to innovation, sustainability, and market leadership.  

Key highlights from the announcement include  

• The board approved fundraising up to Rs 1.50 billion through permissible routes.  
• Rs 1.10 billion will be invested in capacity addition across key product lines.  
• Focus areas include Vitamin D3, Vitamin D3 derivatives, and green chemistry enzyme production.  
• The investment aligns with Fermenta Biotech’s long-term growth strategy and sustainability goals.  
• The company holds ISO certifications and global regulatory approvals, ensuring compliance with international standards.  
• Industry experts view the move as a positive step to strengthen competitiveness in domestic and international markets.  
• The initiative is expected to enhance operational efficiency and support future revenue growth.  

This fundraising and capacity expansion initiative marks a significant milestone for Fermenta Biotech Ltd. By investing in high-demand verticals, the company is positioning itself for sustainable growth and reinforcing its role as a trusted partner in the pharmaceutical and biotechnology industries.  

Sources: Economic Times, Business Standard, Fermenta Biotech Investor Filings